Company News

Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company

Proteologix has bispecific antibodies ready to enter phase 1 and in preclinical development for moderate to severe AD.

Author Image

By: Christine Esposito

Editor-in-Chief

Johnson & Johnson may have spun off its consumer skin health unit—now known as Kenvue—in 2023,  but finding new treatments for challenging skin conditions remains a focus for the healthcare giant. The company is acquiring Proteologix, a privately-held biotech company focused on bispecific antibodies for treatment of severe atopic dermatitis (AD) and other auto immune diseases. Proteologix’s portfolio includes PX128, a bispecific antibody ready to enter phase 1 development for moderate...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters